NCT05067348View on ClinicalTrials.gov

Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 21, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

March 30, 2026

Conditions
Myasthenia Gravis, Generalized
Interventions
DRUG

Tocilizumab Injectable Product

Participants will receive IV tocilizumab

Trial Locations (6)

100050

NOT_YET_RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

200040

NOT_YET_RECRUITING

Huashan Hospital, Shanghai

300052

NOT_YET_RECRUITING

Tianjin medical university general hospital, Tianjin

410008

NOT_YET_RECRUITING

Xiangya Hospital Central South University, Changsha

610041

NOT_YET_RECRUITING

West China Hospital of Sichuan University, Chengdu

710038

RECRUITING

Tangdu Hospital, The Fourth Military Medical University, Xi'an

All Listed Sponsors
lead

Tang-Du Hospital

OTHER